Molecular Targeted Therapies for Patients with Refractory Thyroid Cancer

Abstract The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In pati...

Full description

Saved in:
Bibliographic Details
Published in:Clinical oncology (Royal College of Radiologists (Great Britain)) 2010-08, Vol.22 (6), p.448-455
Main Authors: Chougnet, C, Brassard, M, Leboulleux, S, Baudin, E, Schlumberger, M
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Carcinoma - drug therapy
Carcinoma - pathology
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Disease Progression
Hematology, Oncology and Palliative Medicine
Humans
Protein Kinase Inhibitors - therapeutic use
Radiology
Refractory thyroid cancer
targeted therapy
Thyroid Neoplasms - drug therapy
Thyroid Neoplasms - pathology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.
ISSN:0936-6555
1433-2981
DOI:10.1016/j.clon.2010.04.008